Investing Profile

David Schenkein

VCInvestor

General Partner at GV

gv.com/team/david-schenkein/Boston, Massachusetts

Your Intro Paths to David Schenkein

Signal uses Gmail to reveal intro paths. Email content is never read.

Networks David is a member of

Genentech Network

31 CONNECTIONS

GV Network

29 CONNECTIONS

Find David Schenkein on

Current Investing Position

GV (Google Ventures) General Partner

Investment Range

$250K - $50.0M

Sweet Spot

$25.0M

Investments On Record

Current Fund Size

$8B

David Schenkein is on these Sector & Stage Rankings

BioTech (Series B)Pharmaceuticals (Series B)BioTech (Series A)Pharmaceuticals (Series A)Boston / New England

David Schenkein's Investments On Record (18)

Company	StageDateRound Size	Total Raised
Mestag Therapeutics	Series UnknownMar 2026$40M	$51M
Co-investors: Issi Rozen (GV (Google Ventures)), Houman Ashrafian (SV Health Investors)
EpiBiologics	Series BJan 2026$110M Series AJul 2023$23M	$200M
Co-investors: Anika Gupta (GV (Google Ventures)), Alexandra Cantley (Polaris Partners), Laura Brass (MPM BioImpact), Samuel Bjork (Digitalis Ventures), Alaa Halawa (Mubadala), Gaurav Aggarwal (Vivo Capital), Nisa Leung (Qiming Venture Partners)
Paradigm	Series BDec 2025$78M Series AJan 2023$200M	$320M
Co-investors: Niko Bonatsos (General Catalyst), Elena Viboch (General Catalyst), Hemant Taneja (General Catalyst), Ramnik Arora (FTX Ventures), Max Rimpel (Index Ventures), Bilal Zuberi (Lux Capital), Brett Cook (F-Prime Capital Partners), Stephen Knight (F-Prime Capital Partners), Jay Markowitz (ARCH Venture Partners), Robert Nelsen (ARCH Venture Partners), Alaa Halawa (Mubadala), Justin Kao (DFJ Growth), Jared Friedman (Israel Defense Forces), Scott Belsky (A24), Eoghan McCabe, Arash Ferdowsi, Karim Atiyeh, Balaji Srinivasan
Pelage Pharmaceuticals	Series BOct 2025$120M Series AAug 2024$14M Series AFeb 2024$17M	$150M
Co-investors: Richard Heyman (ARCH Venture Partners)
Treeline Biosciences	Series ASep 2025$200M Series AApr 2021$210M	$410M
Prime Medicine	Post Ipo EquityAug 2025$5M Series BJul 2021$200M Series AOct 2019$120M	$320M
Co-investors: Stephen Knight (F-Prime Capital Partners), Neil Sirni (Proximity Ventures), Stephen Francis (Arrive), Robert Nelsen (ARCH Venture Partners)
Rhygaze	Series AJan 2025$86M	$97M
Co-investors: Florian Müllershausen (Novartis Venture Fund), Daniela Couto (BGV (BioGeneration Ventures))
Leyden Labs	Series BJan 2025$70M Series BJan 2022$140M Series AMar 2021$47M	$260M
Co-investors: Stephen Knight (F-Prime Capital Partners), Brook Byers (Kleiner Perkins), Jeffrey Bird (Bluebird Ventures), Eli Casdin (Casdin Capital), Nisa Leung (Qiming Venture Partners)